Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04889430 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
A Phase 3 study of Atypical Hemolytic-Uremic Syndrome, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
- 20
- Study locations
NCT04889430 is a Phase 3 study of Atypical Hemolytic-Uremic Syndrome that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 34 participants, below the 1,041-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04889430, a Phase 3 study of Atypical Hemolytic-Uremic Syndrome, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Conditions Studied
Interventions
- DRUG Iptacopan
Study Locations (20)
California
- USC Norris Cancer Center - Los Angeles
- Univ of California at Los Angeles - Los Angeles
- Univ Cali Irvine ALS Neuromuscular - Orange
- Univ of California at Sacramento - Sacramento
- Harbor-UCLA Medical Center . - Torrance
Ohio
- University of Cincinnati - Cincinnati
- Cleveland Clinic Foundation - Cleveland
- Comprehensive Transplant Ctr at OSU - Columbus
New Jersey
- St Barnabas Hospital - Livingston
- Rut Univ for Translational Med Scie - New Brunswick
New York
- Montefiore Medical Center . - The Bronx
- Montefiore Medical Center - The Bronx
District of Columbia
- Georgetown University Lombardi Cancer Center - Washington D.C.
Florida
- University Of Miami - Miami
Massachusetts
- Brigham and Womens Hospital - Boston
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2026-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04889430
The ClinicalTrials.gov registry entry for NCT04889430 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,041-participant average among 3 other Atypical Hemolytic-Uremic Syndrome trials with a reported enrollment target (97% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atypical Hemolytic-Uremic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Iptacopan is the first listed.
NCT04889430 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Ohio, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04889430 about?
NCT04889430 is a clinical study titled "Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy". The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
What is the current status of trial NCT04889430?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2022-01-17. Estimated completion is 2026-08-13.
What conditions does trial NCT04889430 study?
This clinical trial studies the following conditions: Atypical Hemolytic-Uremic Syndrome.
What interventions are being tested in trial NCT04889430?
The interventions under investigation include: Iptacopan (DRUG).
Who is sponsoring clinical trial NCT04889430?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04889430 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atypical Hemolytic-Uremic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
ACTIVE NOT RECRUITING · Phase 3
-
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.